Fresenius Medical Care (FMEA) Stock Price & Analysis
FMEA Stock Chart & Stats
- Day’s Range
- EUR 20.20 - EUR 20.20
- 52-Week Range
- EUR 17.20 - EUR 23.60
- Previous Close
- EUR 20.40
- Volume
- N/A
- Average Volume (3M)
- 46
- Market Cap
- EUR 10.73B
- Enterprise Value
- EUR 24.57B
- Total Cash (Recent Filing)
- EUR 1.45B
- Total Debt (Recent Filing)
- EUR 10.96B
- Price to Earnings (P/E)
- 12.2
- Beta
- 0.43
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 0.58
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.66%
Bulls Say, Bears Say
Bulls Say
Profitability And Efficiency Gains
Strong operating income growth and durable FME25+ savings indicate that efficiency initiatives are translating into a structurally better cost base. The 180-basis-point margin expansion can support reinvestment, resilience, and stronger earnings conversion over coming quarters.
Cash Generation
Substantial operating and free cash flow demonstrates that reported earnings are supported by cash generation, giving Fresenius Medical Care capacity to fund clinics, product development, debt service, and shareholder returns while maintaining strategic flexibility.
Dialysis Technology Adoption
Scaling adoption of the 5008X creates a durable platform for recurring consumables demand and reinforces the company’s integrated clinic-and-products model. Broader use of advanced therapy may also strengthen clinical differentiation and support long-term provider relationships.
Bears Say
U.S. Treatment Volume Execution
Persistent negative U.S. same-market treatment growth exposes an execution weakness in referral capture, the core volume driver for Care Delivery. If volumes remain flat or decline, clinic utilization and operating leverage may stay below potential despite cost improvements.
China Regulatory And Portfolio Disruption
China combines ongoing regulatory pressure with a significant portfolio reset, including exiting peritoneal dialysis and discontinuing the 4008A system. One-time costs and strategy uncertainty could weigh on near-term earnings while the localized offering is rebuilt.
Balance-sheet Flexibility
Moderate leverage is manageable, but declining equity alongside broadly steady debt reduces balance-sheet flexibility. This can constrain the company’s room to absorb operational setbacks, finance expansion, or sustain capital returns if earnings or cash flow weaken.
Fresenius Medical Care News
FMEA FAQ
What was Fresenius Medical Care’s price range in the past 12 months?
What is Fresenius Medical Care’s market cap?
When is Fresenius Medical Care’s upcoming earnings report date?
How were Fresenius Medical Care’s earnings last quarter?
Is Fresenius Medical Care overvalued?
Does Fresenius Medical Care pay dividends?
What is Fresenius Medical Care’s EPS estimate?
How many shares outstanding does Fresenius Medical Care have?
What happened to Fresenius Medical Care’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fresenius Medical Care?
What is the TipRanks Smart Score and how is it calculated?
Fresenius Medical Care Stock Smart Score
Company Description
Fresenius Medical Care
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Helen Giza
- Employees
- 108,165
- Website
- www.freseniusmedicalcare.com
- Address
- Else-KrOener Strasse 1, Bad Homburg, HE, 61352, DE
Fresenius Medical Care (FMEA) Earnings & Revenues
FMEA Company Deck
FMEA Earnings Call
Earnings Call SentimentPositive
The call balanced meaningful operational and financial progress against notable execution and external headwinds. Highlights include strong operating income growth (+23%), margin expansion (+180 bps), EUR 67 million of sustainable FME25+ savings, improved cash generation (+11% operating cash flow), a successful 5008X rollout (227 clinics, >600k treatments) and a profitable turnaround in value-based care (EUR 18m operating income). Lowlights include a U.S. referral/capture execution gap driving a 0.9% decline in U.S. same‑market treatments and an expectation that U.S. volumes will remain around the Q2 level for 2026, regulatory and inflationary pressures in China and Care Enablement (EUR ~20m Q2 headwind), a EUR 103m special-item charge (TAVNEOS impairment), and TDAPA timing creating an H2 earnings headwind (net ~EUR 50m for the year). Overall, the positives around profitability, cash flow, capital returns and product rollout outweigh the near-term volume and regulatory challenges, though execution on U.S. referrals and China strategy will be key to sustaining momentum.
View all DE:FMEA earnings summariesFMEA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 1 | 5 |
| Technical Analysis | 4 | 1 | 5 |
| Moving Averages | 12 | 0 | 0 |
